Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Commercial plans.

When does this change take effect?

This change is effective Apr 2, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.01.98c, Teclistamab-cqyv (Tecvayli®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Apr 2, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A commercial insurance policy for Teclistamab-cqyv (Tecvayli®), a specialty pharmacy medication, has been reissued and will be effective April 2, 2025. This is a recent policy update that may affect coverage, prior authorization, or billing requirements for this oncology medication.

Action Required

Action needed

Before April 2, 2025: Billing team and providers should review the updated Teclistamab-cqyv (Tecvayli®) policy details at the source URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures. Update billing protocols and prior authorization workflows as needed for this specialty oncology medication.

Related policy hubs

Independence Blue Cross policies Oncology Hematology